Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.10
Nov 16 • 3:27 PM ET Dollar change-0.18 Percentage change(-14.06%)
Index
RUT
Market Cap
237.29M
Enterprise Value
-38.92M
Income
-189.50M
Sales
0.00M
Book/sh
1.32
Cash/sh
1.39
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
156
IPO
Oct 25, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.84
P/C
0.79
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
6.55
Current Ratio
6.55
Debt/Eq
0.08
LT Debt/Eq
0.02
Option/Short
Yes / Yes
EPS (ttm)
-1.43
EPS next Y
-1.06
EPS next Q
-0.27
EPS this Y
40.22%
EPS next Y
15.79%
EPS next 5Y
23.64%
EPS past 3/5Y
-5.18% -7.84%
Sales past 3/5Y
- -
EPS Y/Y TTM
43.51%
Sales Y/Y TTM
-
EPS Q/Q
35.26%
Sales Q/Q
-
Insider Own
11.59%
Insider Trans
0.00%
Inst Own
78.27%
Inst Trans
27.63%
ROA
-72.02%
ROE
-89.52%
ROIC
-65.54%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-22.86%
SMA50
-41.48%
SMA200
-60.51%
Trades
Shs Outstand
215.72M
Shs Float
190.72M
52W High
4.23 -74.00%
52W Low
1.18 -6.78%
Volatility
10.09% 9.96%
ATR (14)
0.15
RSI (14)
29.46
Beta
3.55
Rel Volume
0.76
Avg Volume
5.32M
Volume
3,711,449
Perf Week
-26.67%
Perf Month
-21.99%
Perf Quarter
-62.20%
Perf Half Y
-66.57%
Perf YTD
-49.77%
Perf Year
-52.38%
Perf 3Y
-93.69%
Perf 5Y
-90.82%
Perf 10Y
-
Prev Close
1.28
Price
1.10
Change %
-14.06%
Consensus
Strong Buy
Avg. Price Target
$11.75
Implied Upside
+968.2%
Analysts14incl. previous ratings
Rating Distribution12 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 10, 2025Resumed
JEF logoJJefferies
Buy$14+1,172.7%
Dec 20, 2024Downgrade
EVR logoEEvercore ISI
Outperform → In-line$15 → $6+445.5%
Dec 19, 2024Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$12 → $6+445.5%
Oct 10, 2024Initiated
UBS logoUUBS
Buy$10+809.1%
Feb 05, 2024Initiated
JEF logoJJefferies
Buy$36+3,172.7%
Nov 29, 2023Initiated
WWilliam Blair
Outperform$38+3,354.5%
Oct 24, 2023Initiated
CCantor Fitzgerald
Overweight$40+3,536.4%
Oct 19, 2023Initiated
SF logoSStifel
Buy$31+2,718.2%
Sep 05, 2023Initiated
C logoCCitigroup
Buy$22+1,900.0%
Jul 18, 2023Initiated
GGuggenheim
Buy$34+2,990.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chang David J.Chief Medical OfficerJan 21 '26Buy2.268,80019,8888,800Jan 21 06:56 PM
Binder GwendolynPresident, Science & Tech.Jan 21 '26Buy2.1911,31224,76331,312Jan 21 06:56 PM
Tomasello ShawnDirectorJan 21 '26Buy2.2122,72550,32222,725Jan 21 06:55 PM
Gavel SteveChief Commercial OfficerJan 21 '26Buy2.2722,17050,21522,170Jan 21 06:55 PM
Bollard CatherineDirectorJan 21 '26Buy2.274,4059,9825,405Jan 21 06:54 PM
Nichtberger StevenPresident & CEOJan 21 '26Buy2.2445,000100,7781,031,483Jan 21 06:54 PM
Simon MarkDirectorJan 21 '26Buy2.2811,06125,261147,205Jan 21 06:53 PM
Gerard MichaelGeneral CounselJan 21 '26Buy2.276,60014,9796,600Jan 21 06:53 PM
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Co-FounderDr. Steven A. Nichtberger M.D.
M.D.Dr. David J. Chang FACR
President of Science & TechnologyDr. Gwendolyn K. Binder Ph.D.
Ph.D.Dr. Michael C. Milone M.D.
Ph.D.Dr. Aimee Payne M.D.